Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Belgian scientists in Nature with cancer breakthrough

Scientists Peter Carmeliet and Sarah-Maria Fendt (KU Leuven/VIB) published in the prestigious Nature journal on their fundamental breakthrough in …


ThromboGenics and VIB found oncology company

Oncurious is a new oncology company that will perform clinical trials for the development of TB-403. This compound is a new promising agent for…


Congrats to Biocartis!

The Mechelen-based biotech company Biocartis starts its IPO adventure. The demand for shares was 6,5 times higher than the offer. Biocartis gather…

POPULAR TAGS

Alphabodies for cancer treatment by Complix-Merck collaboration

Written by DS on in the category news with the tags .


The Hasselt-based company Complix entered into a collaboration with Merck (MSD), for development of Alphabodies™. Alphabodies™ are synthetic cell-penetrating antibodies (CPABs) for the treatment of cancer.

Complix will deliver CPABs to Merck against two intracellular cancer targets. Merck will fund these research activities and has the option to obtain the exclusive rights for the resulting compounds. Complix will receive an upfront payment, potential milestones of up to 280 million dollars and royalties.

Mark Vaeck, CEO of Complix says: “This collaboration highlights the potential of our unique CPAB platform, delivering game changing biotherapeputics for the treatment of cancer. I am very much looking forward to working with the team of MSD.”

Read more about: .

RELATED ARTICLES
Belgian scientists in Nature with cancer breakthrough

Scientists Peter Carmeliet and Sarah-Maria Fendt (KU Leuven/VIB) published in the prestigious Nature journal on their fundamental breakthrough in …


ThromboGenics and VIB found oncology company

Oncurious is a new oncology company that will perform clinical trials for the development of TB-403. This compound is a new promising agent for…


Congrats to Biocartis!

The Mechelen-based biotech company Biocartis starts its IPO adventure. The demand for shares was 6,5 times higher than the offer. Biocartis gather…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Turnstone V-Bio Ventures Janssen GSK Flanders.bio Biowin Itera Life Science XpandInnovation UGent KU Leuven

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.